

Are your MRI contrast agents cost-effective?

Learn more about generic Gadolinium-Based Contrast Agents.



AJNR

Association between Cerebral Microbleeds on T2*-Weighted MR Images and Recurrent Hemorrhagic Stroke in Patients Treated with Warfarin following Ischemic Stroke

H. Ueno, H. Naka, T. Ohshita, K. Kondo, E. Nomura, T. Ohtsuki, T. Kohriyama, S. Wakabayashi and M. Matsumoto

This information is current as of April 17, 2024.

AJNR Am J Neuroradiol 2008, 29 (8) 1483-1486
doi: <https://doi.org/10.3174/ajnr.A1120>
<http://www.ajnr.org/content/29/8/1483>

ORIGINAL
RESEARCH

H. Ueno
H. Naka
T. Ohshita
K. Kondo
E. Nomura
T. Ohtsuki
T. Kohriyama
S. Wakabayashi
M. Matsumoto

Association between Cerebral Microbleeds on T2*-Weighted MR Images and Recurrent Hemorrhagic Stroke in Patients Treated with Warfarin following Ischemic Stroke

BACKGROUND AND PURPOSE: Although accumulating evidence suggests the presence of microbleeds as a risk factor for intracerebral hemorrhage (ICH), little is known about its significance in anticoagulated patients. The aim of this study was to determine whether the presence of microbleeds is associated with recurrent hemorrhagic stroke in patients who had received warfarin following atrial fibrillation-associated cardioembolic infarction.

MATERIALS AND METHODS: A total of 87 consecutive patients with acute recurrent stroke, including 15 patients with ICH and 72 patients with cerebral infarction, were enrolled in this study. International normalized ratios (INRs), vascular risk factors, and imaging characteristics, including microbleeds on T2*-weighted MR images and white matter hyperintensity (WMH) on T2-weighted MR images, were compared in the 2 groups.

RESULTS: Microbleeds were noted more frequently in patients with ICH than in patients with cerebral infarction (86.7% versus 38.9%, $P = .0007$). The number of microbleeds was larger in patients with ICH than in patients with cerebral infarction (mean, 8.4 versus 2.1; $P = .0001$). INR was higher in patients with ICH than in patients with cerebral infarction (mean, 2.2 versus 1.4; $P < .0001$). The frequency of hypertension was higher in patients with ICH than in patients with cerebral infarction (86.7% versus 45.8%, $P = .0039$). Multivariate analysis revealed that the presence of cerebral microbleeds (odds ratio, 7.383; 95% confidence interval, 1.052–51.830) was associated with ICH independent of increased INR and hypertension.

CONCLUSION: The presence of cerebral microbleeds may be an independent risk factor for warfarin-related ICH, but more study is needed because of strong confounding associations with elevated INR and hypertension.

One of the major complications of warfarin treatment following atrial fibrillation-related cardioembolic infarction is the occurrence of intracerebral hemorrhage (ICH). With advancing age, the incidence of both atrial fibrillation-related cardioembolic infarction and warfarin-related ICH increases.

Cerebral microbleeds detected by gradient-echo T2*-weighted MR imaging, which are shown as signal-intensity loss, represent hemosiderin deposit^{1,2} and are associated with occurrence of ICH.³⁻¹⁹ Although accumulating evidence suggests that the presence of microbleeds is a risk factor for ICH in patients treated by antiplatelet therapy^{13,20} and hemorrhagic complications of anticoagulation in patients with prior ICH and atrial fibrillation have been reported,²¹ little is known about the significance of microbleeds in anticoagulated patients because, to our knowledge, no studies have focused on the association between cerebral microbleeds and anticoagulation therapy in a large number of patients. On the other hand, previous studies focusing on radiographic characteris-

tics have shown that the presence of microangiopathy (leukoaraiosis) detected by CT is a risk factor for warfarin-related ICH.²² However, considering the close association between cerebral microbleeds and leukoaraiosis (white matter hyperintensity [WMH]),^{7,8,11,14-16,19,23,24} one could hypothesize that cerebral microbleeds, which represent bleeding from small vessels, may be more closely associated with ICH than WMH is. Therefore, the present study was performed to determine whether the presence of microbleeds is associated with recurrent hemorrhagic stroke in patients who have received warfarin treatment following atrial fibrillation-associated cardioembolic infarction.

Materials and Methods

We prospectively evaluated inpatients with acute recurrent stroke who had received warfarin treatment following nonvalvular atrial fibrillation-associated cardioembolic infarction and who had undergone MR imaging studies in our hospital during the period from September 2002 to August 2007. Patients with valvular infarcts were excluded because they might have received a different anticoagulation regimen, and patients with arterial-origin infarcts were also excluded because they might not have been anticoagulated. Patients with hemorrhagic stroke or hemorrhagic conversion of the initial infarction were also excluded. Diagnosis of acute recurrent stroke was made on the basis of neurologic signs and symptoms and results of neuro-radiologic examinations. Stroke was classified into ICH and ischemic stroke. ICH was diagnosed by CT, and acute ischemic stroke was confirmed by diffusion-weighted imaging (DWI) and apparent diffusion coefficient maps.

Received November 14, 2007; accepted after revision March 11, 2008.

From the Department of Clinical Neuroscience and Therapeutics, (H.U., T.O., K.K., E.N., T.O., T.K., M.M.), Hiroshima University, Graduate School of Biomedical Sciences, Hiroshima, Japan; and Departments of Neurology (H.N.) and Neurosurgery (S.W.), Suiseikai Kajikawa Hospital, Hiroshima, Japan.

This work was partially supported by research grants from the Ministry of Health, Labor and Welfare, Japan, and from the Smoking Research Foundation, Japan.

Please address correspondence to Hiroki Ueno, MD, Department of Clinical Neuroscience and Therapeutics, Hiroshima University, Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan; e-mail: hirokiueno@hiroshima-u.ac.jp

DOI 10.3174/ajnr.A1120

All patients were examined by using a 1.5T clinical MR imaging unit (Magnetom Symphony; Siemens, Erlangen, Germany), and the whole brain was scanned with a section thickness of 5 mm and a 1.5-mm intersection gap. The imaging protocol consisted of axial T2-weighted spin-echo sequences (TR/TE, 3800/99 ms; FOV, 220 × 220; matrix, 256 × 512), axial T2*-weighted gradient-echo sequences (TR/TE, 800/26 ms; flip angle, 20°; FOV, 230 × 230; matrix, 192 × 256), and DWI with single-shot echo-planar spin-echo sequences (TR/TE, 5300/135 ms; FOV, 196 × 261; matrix, 80 × 128; b-values, 0 and 1000 s/mm²). Patients who were unable to be evaluated by MR imaging because of artifacts were excluded.

Microbleeds were defined as homogeneous round signal-intensity-loss lesions on T2*-weighted MR images, excluding lesions in the globus pallidum and the subarachnoid space, which are likely to represent calcification and adjacent pial blood vessels, respectively. Intracerebral lesions with a hemorrhagic component associated with tumors, arteriovenous malformations, cavernomas, and abscesses were also excluded. WMH on T2-weighted images was graded by using the scoring system of Fazekas et al²⁵ into 4 grades: grade 0 = absent, 1 = punctate, 2 = early confluent, and 3 = confluent. WMH of grade 2 or 3 was regarded as advanced WMH. MR images were evaluated by 2 of the authors (H.N., H.U.) separately without knowledge of the patients' clinical profiles, and the number of microbleeds and the grading scores of WMH were determined by consensus.

In all patients, international normalized ratios (INRs) were evaluated by using blood taken before starting acute therapy. Hypertension was defined as systolic blood pressure of ≥140 mm Hg and diastolic blood pressure of ≥90 mm Hg before recurrence of stroke or occurring in patients currently undergoing medical treatment for hypertension. Diabetes mellitus was defined as a glycosylated hemoglobin A1c concentration of >5.8% or occurring in patients currently using hypoglycemic agents. Hypercholesterolemia was defined as a total cholesterol level of ≥220 mg/dL or occurring in patients currently undergoing cholesterol-lowering therapy. Whether patients had undergone antiplatelet therapy before occurrence of stroke was recorded.

All values are expressed as means ± SD. Among ICH and cerebral infarction, the χ^2 test for independence was used for comparison of sex ratio, hypertension, diabetes mellitus, hypercholesterolemia, antiplatelet therapy, microbleeds, and advanced WMH; the Student *t* test was used for comparison of age and INRs; and the Mann-Whitney *U* test was used for comparison of the number of microbleeds. Logistic regression analysis was used to assess the relationships of ICH with the following variables: age, sex, INR, hypertension, diabetes mellitus, hypercholesterolemia, antiplatelet therapy, advanced WMH, and microbleeds.

Results

The study population consisted of 87 patients with acute recurrent stroke, including 72 patients (49 men and 23 women; mean age, 74.5 ± 11.7 years) with cerebral infarction and 15 patients (8 men and 7 women; mean age, 77.1 ± 9.6 years) with ICH. The patients' backgrounds are summarized in Table 1. No significant difference was found in age, sex ratio, or frequencies of advanced WMH, diabetes mellitus, hypercholesterolemia, or antiplatelet therapy between the cerebral infarction and ICH groups. In contrast, microbleeds were noted more frequently in patients with ICH than in patients with cerebral infarction (86.7% versus 38.9%, *P* = .0007). The number of microbleeds was larger in patients with ICH than in

Table 1: Background of the patients

Characteristics	ICH (<i>n</i> = 15)	Ischemic Stroke (<i>n</i> = 72)	<i>P</i> Value
Male sex, no. (%)	8 (53.3)	49 (68.1)	.28
Age (yr), mean (SD)	77.1 (9.6)	74.6 (11.6)	.43
Frequency of MBs, no. (%)	13 (86.7)	28 (38.9)	.0007
No. of MBs, no., mean (SD)	8.4 (14.0)	2.1 (2.1)	.0001
WMH, no. (%)	8 (53.3)	23 (31.9)	.12
Antiplatelet therapy, no. (%)	4 (26.7)	18 (25.0)	.89
Hypertension, no. (%)	13 (86.7)	33 (45.8)	.0039
Diabetes mellitus, no. (%)	4 (26.7)	18 (25.0)	.89
Hypercholesterolemia, no. (%)	3 (20.0)	14 (19.4)	.96
INR, mean (SD)	2.20 (1.13)	1.41 (0.51)	<.0001

Note:—MBs indicates microbleeds; WMH, white matter hyperintensity; INR, international normalized ratio.

patients with cerebral infarction (range, 0–54 versus 0–38; mean, 8.4 versus 2.1; *P* = .0001). Representative images of a patient with ICH and a patient with recurrent cardioembolic infarction are shown in Figs 1 and 2, respectively. INR was higher in patients with ICH than in patients with cerebral infarction (mean, 2.2 versus 1.4; *P* < .0001). The frequency of hypertension was higher in patients with ICH than in patients with cerebral infarction (86.7% versus 45.8%, *P* = .0039). Multivariate analysis revealed that increased INR (odds ratio, 5.119; 95% confidence interval [CI], 1.614–16.239), presence of cerebral microbleeds (odds ratio, 7.383; 95% CI, 1.052–51.830), and hypertension (odds ratio, 13.599; 95% CI, 1.653–111.898) were independently associated with ICH (Table 2).

Discussion

The present study demonstrated that the presence of cerebral microbleeds was associated with ICH independent of increased INR and hypertension in patients with cerebral infarction following atrial fibrillation-related cardioembolic infarction. Although some studies have been performed to determine whether the use of antiplatelet therapy is associated with the occurrence of ICH in patients with microbleeds,¹³ this is the first study aimed at determining whether the presence of microbleeds is associated with recurrent hemorrhagic stroke in patients who had undergone warfarin treatment following atrial fibrillation-associated cardioembolic infarction.

Although it has been established that warfarin treatment is effective for preventing cerebral embolism arising from atrial fibrillation, the most serious adverse event in atrial fibrillation is hemorrhage complication. An excess incidence of major bleeding (7% per year) in patients with nondisabling cerebral ischemia of presumed arterial origin and treated with oral anticoagulation led to early termination of the Stroke Prevention in Reversible Ischemia Trial (SPIRIT).²⁶ As for radiographic characteristics as risk factors for warfarin-related ICH, the presence of advanced leukoaraiosis has been reported.^{22,27} Gorter²⁷ assessed independent predictors of hemorrhage in 651 anticoagulated patients after cerebral ischemia in SPIRIT and reported that leukoaraiosis detected by CT, intensity of anticoagulation, and age older than 65 years are independent risk factors for bleeding in anticoagulated patients. Smith et al²² compared radiographic and clinical characteristics of 26 patients with warfarin-related ICH following ischemic stroke with those of 56 controls, and they reported that the presence




Fig 1. MR images of a patient with intracerebral hemorrhage in the left thalamus. T2*-weighted images reveal multiple foci of signal-intensity loss (microbleeds) in the brain stem, thalamus, and cerebral hemispheres.




Fig 2. MR images of a patient with recurrent cardioembolic infarction. A, DWI shows hyperintense signal-intensity alterations in the right frontal lobe, indicating acute cerebral infarction. B and C, T2*-weighted images do not show cerebral microbleeds.

Table 2: Logistic regression analysis

Variable	Odds Ratio	95% CI	P Value
Age	1.06	0.982–1.144	.1352
INR	5.119	1.614–16.239	.0056
Sex	0.967	0.194–4.816	.9677
MBs	7.383	1.052–51.830	.0443
WMH	1.234	0.227–6.722	.8077
Antiplatelet therapy	0.662	0.105–4.178	.6603
Hypertension	13.599	1.653–111.898	.0152
Diabetes mellitus	1.424	0.175–11.613	.7414
Hypercholesterolemia	2.06	0.301–14.106	.4617

Note:—MBs indicates microbleeds; WMH, white matter hyperintensity; INR, international normalized ratio.

and severity of leukoaraiosis detected by CT were independent risk factors for poststroke warfarin-related ICH.

These results indicate that warfarin may trigger ICH in patients with severe disturbance of cerebral small arteries. In contrast, our results showed that the presence of microbleeds, but not advanced WMH, was an independent risk factor of poststroke warfarin-related ICH. This discrepancy may be explained by the pathologic difference between microbleeds and

WMH. For instance, though both microbleeds and WMH are associated with small-vessel diseases and often coexist, microbleeds are a bleeding-prone small-vessel disease and WMH is an ischemic small-vessel disease. In fact, some previous studies have shown that the presence of microbleeds is a predictor of ICH in patients with no or mild leukoaraiosis.^{7,19} On the other hand, it was also revealed that patients with advanced leukoaraiosis but without microbleeds tend to be associated with ischemic stroke rather than ICH.¹⁹ In a study using 3 autopsied brains, microbleeds were revealed to be associated with hemosiderin deposit that had been caused by a rupture of arteriosclerotic microvessels, supporting the notion that microbleeds are associated with fragility of blood vessels.¹ INR in the ICH group was much higher than that in the cerebral infarction group, and INR was an independent risk factor for ICH in our study. Excess anticoagulation itself may have resulted in the occurrence of ICH, whereas hemorrhagic diathesis may have predisposed to microbleeds and ICH with the use of warfarin.

The results of the present study also showed that the fre-

quency of hypertension was higher in patients with ICH than in patients with cerebral infarction and was an independent risk factor of warfarin-related ICH. Although it has been shown that hypertension is a major risk factor of microbleeds^{1,4,15,18,28,29} and ICH, it remains to be clarified whether hypertension management in the presence of microbleeds prevents the occurrence of ICH. Strict management of hypertension in anticoagulated patients with microbleeds is important in preventing the occurrence of ICH, but further studies are needed to confirm this.

Our study has some limitations. Because we could see the hematoma in patients with ICH when evaluating microbleeds on T2*-weighted MR images, this study was not a completely blind trial; therefore, bias could not be avoided. In addition, the duration of anticoagulant medication was not recorded in the present study. It remains to be determined whether the duration of anticoagulant medication affects the presence of microbleeds and the occurrence of ICH. It would also be informative to have included a control group of patients who were not treated with warfarin to estimate to what extent warfarin increases the risk of ICH in patients with microbleeds above their untreated incidence. In addition, patients with arterial embolic strokes who are not anticoagulated would be an additional and important group. Further studies are needed to clarify such issues.

Conclusions

The results of the present study suggest that evaluation of the presence of cerebral microbleeds as a risk factor for ICH in patients being treated with warfarin deserves study in a blind and controlled prospective therapeutic trial.

References

1. Tanaka A, Ueno Y, Nakayama Y, et al. Small chronic hemorrhages and ischemic lesions in association with spontaneous intracerebral hematomas. *Stroke* 1999;30:1637–42
2. Fazekas F, Kleinert R, Roob G, et al. Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. *AJNR Am J Neuroradiol* 1999;20:637–42
3. Greenberg SM, O'Donnell HC, Schaefer PW, et al. MRI detection of new hemorrhages: potential marker of progression in cerebral amyloid angiopathy. *Neurology* 1999;53:1135–38
4. Roob G, Lechner A, Schmidt R, et al. Frequency and location of microbleeds in patients with primary intracerebral hemorrhage. *Stroke* 2000;31:2665–69
5. Kinoshita T, Okudera T, Tamura H, et al. Assessment of lacunar hemorrhage associated with hypertensive stroke by echo-planar gradient-echo T2*-weighted MRI. *Stroke* 2000;31:1646–50
6. Hermier M, Nighoghossian N, Derex L, et al. MRI of acute post-ischemic cerebral hemorrhage in stroke patients: diagnosis with T2*-weighted gradient-echo sequences. *Neuroradiology* 2001;43:809–15
7. Kim DE, Bae HJ, Lee SH, et al. Gradient-echo magnetic resonance imaging in the prediction of hemorrhagic vs ischemic stroke: a need for the consideration of the extent of leukoaraiosis. *Arch Neurol* 2002;59:425–29
8. Tsushima Y, Aoki J, Endo K. Brain microhemorrhages detected on T2*-weighted gradient-echo MR images. *AJNR Am J Neuroradiol* 2003;24:88–96
9. Kidwell CS, Saver JL, Villablanca JP, et al. Magnetic resonance imaging detection of microbleeds before thrombolysis: an emerging application. *Stroke* 2002;33:95–98
10. Nighoghossian N, Hermier M, Adeleine P, et al. Old microbleeds are a potential risk factor for cerebral bleeding after ischemic stroke: a gradient-echo T2*-weighted brain MRI study. *Stroke* 2002;33:735–42
11. Kato H, Izumiyama M, Izumiyama K, et al. Silent cerebral microbleeds on T2*-weighted MRI: correlation with stroke subtype, stroke recurrence, and leukoaraiosis. *Stroke* 2002;33:1536–40
12. Fan YH, Zhang L, Lam WW, et al. Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke. *Stroke* 2003;34:2459–62
13. Wong KS, Chan YL, Liu JY, et al. Asymptomatic microbleeds as a risk factor for aspirin-associated intracerebral hemorrhages. *Neurology* 2003;60:511–13
14. Naka H, Nomura E, Wakabayashi S, et al. Frequency of asymptomatic microbleeds on T2*-weighted MR images of patients with recurrent stroke: association with combination of stroke subtypes and leukoaraiosis. *AJNR Am J Neuroradiol* 2004;25:714–19
15. Lee SH, Bae HJ, Kwon SJ, et al. Cerebral microbleeds are regionally associated with intracerebral hemorrhage. *Neurology* 2004;62:72–76
16. Jeong SW, Jung KH, Chu K, et al. Clinical and radiologic differences between primary intracerebral hemorrhage with and without microbleeds on gradient-echo magnetic resonance images. *Arch Neurol* 2004;61:905–09
17. Koennecke HC. Cerebral microbleeds on MRI: prevalence, associations, and potential clinical implications. *Neurology* 2006;66:165–71
18. Viswanathan A, Chabriat H. Cerebral microhemorrhage. *Stroke* 2006;37:550–55
19. Naka H, Nomura E, Takahashi T, et al. Combinations of the presence or absence of cerebral microbleeds and advanced white matter hyperintensity as predictors of subsequent stroke types. *AJNR Am J Neuroradiol* 2006;27:830–35
20. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. *Stroke* 2005;36:1588–93
21. Eckman MH, Rosand J, Knudsen KA, et al. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. *Stroke* 2003;34:1710–16
22. Smith EE, Rosand J, Knudsen KA, et al. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. *Neurology* 2002;59:193–97
23. Kwa VI, Franke CL, Verbeeten B Jr., et al. Silent intracerebral microhemorrhages in patients with ischemic stroke. *Ann Neurol* 1998;44:372–77
24. Hanyu H, Tanaka Y, Shimizu S, et al. Cerebral microbleeds in Binswanger's disease: a gradient-echo T2*-weighted magnetic resonance imaging study. *Neurosci Lett* 2003;340:213–16
25. Fazekas F, Chawluk JB, Alavi A, et al. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. *AJR Am J Roentgenol* 1987;149:351–56
26. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin: The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. *Ann Neurol* 1997;42:857–65
27. Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. *Neurology* 1999;53:1319–27
28. Roob G, Schmidt R, Kapeller P, et al. MRI evidence of past cerebral microbleeds in a healthy elderly population. *Neurology* 1999;52:991–94
29. Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain microbleeds: systematic review. *Brain* 2007;130:1988–2003